This report examines current market trends and future opportunities in epilepsy treatment, one of the most common neurological disorders affecting around 50 million people globally and approximately 3.5 million individuals in the United States. The market is driven by the rising incidence of neurological disorders, increasing adoption of third-generation anti-epileptic drugs (AEDs), and growing demand for improved treatment options for refractory patients who often require multiple medications. Key challenges include generic competition, patient non-adherence to therapy, and limited access to specialized neurological care centers. The United States remains the largest market due to its high disease prevalence, while Europe holds the second-largest share and Asia-Pacific is the fastest-grow

Join for free to read